Sanofi
SNYNF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $13,170,000 | $10,735,000 | $10,606,000 | $11,420,000 |
| % Growth | 22.7% | 1.2% | -7.1% | – |
| Cost of Goods Sold | $3,412,000 | $2,992,000 | $2,889,000 | $2,271,000 |
| Gross Profit | $9,758,000 | $7,743,000 | $7,717,000 | $7,844,000 |
| % Margin | 74.1% | 72.1% | 72.8% | 68.7% |
| R&D Expenses | $1,834,000 | $1,909,000 | $1,808,000 | $2,119,000 |
| G&A Expenses | $0 | -$2,185,000 | $0 | $0 |
| SG&A Expenses | $2,291,000 | $2,630,000 | $2,222,000 | $1,242,000 |
| Sales & Mktg Exp. | $0 | $4,506,000 | $0 | $0 |
| Other Operating Expenses | $2,010,000 | $1,730,000 | $1,402,000 | $1,426,000 |
| Operating Expenses | $6,135,000 | $6,269,000 | $5,432,000 | $4,787,000 |
| Operating Income | $3,623,000 | $1,474,000 | $2,285,000 | $1,185,000 |
| % Margin | 27.5% | 13.7% | 21.5% | 10.4% |
| Other Income/Exp. Net | -$115,000 | -$7,000 | -$85,000 | -$115,000 |
| Pre-Tax Income | $3,508,000 | $1,467,000 | $2,200,000 | $1,070,000 |
| Tax Expense | $680,000 | $230,000 | $481,000 | $190,000 |
| Net Income | $2,802,000 | $3,940,000 | $1,872,000 | $683,000 |
| % Margin | 21.3% | 36.7% | 17.7% | 6% |
| EPS | 2.3 | 3.19 | 1.52 | 0.4 |
| % Growth | -27.9% | 109.9% | 280% | – |
| EPS Diluted | 2.27 | 3.19 | 1.52 | 0.4 |
| Weighted Avg Shares Out | 1,218,100 | 1,233,900 | 1,233,900 | 1,249,400 |
| Weighted Avg Shares Out Dil | 1,233,900 | 1,233,900 | 1,233,900 | 1,253,600 |
| Supplemental Information | – | – | – | – |
| Interest Income | $114,000 | $76,000 | $86,000 | $37,000 |
| Interest Expense | $227,000 | $87,000 | $213,000 | $96,000 |
| Depreciation & Amortization | $479,000 | $378,000 | $399,000 | $209,000 |
| EBITDA | $4,214,000 | $1,889,000 | $2,770,000 | $563,000 |
| % Margin | 32% | 17.6% | 26.1% | 4.9% |